The power to "di-sc-seq-t"
- PMID: 33577786
- DOI: 10.1016/j.ccell.2021.02.001
The power to "di-sc-seq-t"
Abstract
In melanoma, intratumoral T-VEC is thought to work through viral replication and destruction of cancer cells, thereby stimulating an immune response. In this issue of Cancer Cell, Ramelyte et al. show activity of T-VEC in cutaneous B cell lymphoma and demonstrate, using scRNA-seq, that viral replication occurs not only in tumor cells.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.B.H. has received (institutional) financial compensation for advisory roles for Achilles Therapeutics, BioNTech, BMS, Gadeta, Immunocore, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, and Third Rock Ventures. J.B.H. received institutional research grants from Amgen, BioNTech, BMS, MSD, and Novartis. J.B.H. holds stock options for Neogene Therapeutics.
Comment on
-
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.Cancer Cell. 2021 Mar 8;39(3):394-406.e4. doi: 10.1016/j.ccell.2020.12.022. Epub 2021 Jan 21. Cancer Cell. 2021. PMID: 33482123
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
